MedPath

PA.RI.GE. Study. The Prognostic Role of Inflammatory Circulating Biomarkers in HNSCC: a Prospective Multicentric Trial

Conditions
Head and Neck Cancer
Registration Number
NCT06809673
Lead Sponsor
Ospedale Policlinico San Martino
Brief Summary

This is a clinical, observational, non-pharmacological, multicenter, prospective case-control no-profit study to assess the prognostic role of several circulating inflammatory biomarkers

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
400
Inclusion Criteria
  1. Age > 18 years;
  2. Written informed consent;
  3. Squamous carcinoma of the hypopharynx, larynx and oral cavity;
  4. Clinical stage I-IVa according to the VIII edition of AJCC staging system
  5. Primary surgery as first line curative intent treatment, followed by ± adjuvant radiotherapy± chemotherapy based on the pathological findings following the NCCN guidelines
Exclusion Criteria
  1. Relapsing or metastatic disease
  2. Locally advanced disease not amenable to curative intent treatment
  3. Previous local or systemic treatment for head and neck cancer
  4. Previous malignancies (exluding non-melanoma skin cancers) unless complete remission has been achieved at least 5 years before entering the study
  5. Psychiatric disorder or known substance abuse
  6. Concomitant immunosuppressive treatment
  7. Concomitant immunostimulant treatment
  8. Chronic inflammatory disease
  9. Autoimmune disease
  10. Major surgery in the previous year
  11. History of recent onset of any condition which, in the investigator's opinion, could interfere with patient adherence for the entire duration of the protocol.
  12. Positive serum pregnancy test for women of childbearing age. Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To identify a profile of circulating biomarkers in patients affected by HNSCC72 months
To identify a subset of patients in which biomarkers modifications might anticipate disease recurrence72 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

IRCCS Policlinico San Martino

🇮🇹

Genoa, Italy

© Copyright 2025. All Rights Reserved by MedPath